Two medicines, side by side
Adalimumab vs risankizumab
Adalimumab and risankizumab are both labeled for crohn's disease and ulcerative colitis and psoriasis. Pharmacies paid $1,587.82 per mL (Adalimumab-adaz(cf) pen 40 mg/0.4 mL) and $22,774.36 per mL (Skyrizi 150 mg/mL pen) (NADAC, October 7, 2026); the strengths differ and one is a brand and one a generic, so the two prices are not like for like. In FDA's classes, adalimumab is a tumor necrosis factor blocker and risankizumab an interleukin-23 antagonist.
Check it at the source: the adalimumab FDA label on DailyMed (effective October 21, 2025); the risankizumab FDA label on DailyMed (effective June 15, 2026).
Highlights of the adalimumab record
Adalimumab (Humira) · label of October 21, 2025
SERIOUS INFECTIONS and MALIGNANCY SERIOUS INFECTIONS Patients treated with adalimumab products, including Adalimumab-adaz, are at increased risk for developing serious infections that may lead to hospitalization or death [see Warnings and Precautions ( 5.1 )]. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. Discontinue Adalimumab-adaz if a patient develops a serious infection or sepsis.
Used for
From the label: indicationsAdalimumab-adaz is a tumor necrosis factor (TNF)-blocker indicated for: • Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis. […]
On the market
- Earliest approval on file
- December 31, 2002
- Generic labelers
- none listed
- Pharmacy cost
- $1,587.82 per mL
Supply and safety
- Shortage
- No current entry
- Recalls
- 1
Highlights of the risankizumab record
Risankizumab (Skyrizi) · label of June 15, 2026
Used for
From the label: indicationsSKYRIZI is an interleukin-23 antagonist indicated for the treatment of: moderate-to-severe plaque psoriasis in adults and pediatric patients 6 years of age and older who are candidates for systemic therapy or phototherapy. ( 1.1 ) active psoriatic arthritis in adults and pediatric patients 6 years of age and older. ( 1.2 ) moderately to severely active Crohn's disease in adults. […]
On the market
- Earliest approval on file
- n/a
- Generic labelers
- none listed
- Pharmacy cost
- $22,774.36 per mL
Supply and safety
- Shortage
- No current entry
- Recalls
- 0
Source: FDA drug labels via openFDA (Adalimumab label of October 21, 2025, Risankizumab label of June 15, 2026); NDC Directory, Drugs@FDA, NADAC, FDA shortages and recalls (October 8, 2026)
How do adalimumab and risankizumab differ on the record?
In FDA's classes, adalimumab is a tumor necrosis factor blocker and risankizumab an interleukin-23 antagonist.
How each works, in its label's words: Adalimumab, “Adalimumab products bind specifically to TNF-alpha and block its interaction with the p55 and p75 cell surface TNF receptors.”; Risankizumab, “Risankizumab-rzaa is a humanized IgG1 monoclonal antibody that selectively binds to the p19 subunit of human IL-23 cytokine and inhibits its interaction with the IL-23 receptor.”
Half-life, in each label's words: Adalimumab, “The mean terminal half-life was approximately 2 weeks, ranging from 10 to 20 days across studies.”; Risankizumab, “Elimination The estimated systemic clearance (inter-subject CV%) was 0.31 L/day (24%) and 0.30 L/day (34%) and terminal …”
Only the adalimumab label carries a boxed warning.
| Adalimumab | Risankizumab | |
|---|---|---|
| Labeled for | Rheumatoid arthritis, Crohn's disease and ulcerative colitis, Psoriasis | Psoriasis, Crohn's disease and ulcerative colitis |
| Pharmacologic class | Tumor Necrosis Factor Blocker | Interleukin-23 Antagonist |
| How it works (label) | Adalimumab products bind specifically to TNF-alpha and block its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab products also lyse surface TNF expressing cells in vitro in the presence of complement. | Risankizumab-rzaa is a humanized IgG1 monoclonal antibody that selectively binds to the p19 subunit of human IL-23 cytokine and inhibits its interaction with the IL-23 receptor. |
| Half-life (label) | The mean terminal half-life was approximately 2 weeks, ranging from 10 to 20 days across studies. | Elimination The estimated systemic clearance (inter-subject CV%) was 0.31 L/day (24%) and 0.30 L/day (34%) and terminal elimination half-life was approximately 28 days and 21 days in subjects with plaque psoriasis and … |
| Earliest approval on file (Drugs@FDA) | December 31, 2002 | n/a |
| First generic approved | none | none |
| Generic labelers (NDC) | none listed | none listed |
| Pharmacy cost (NADAC, each one's most listed form; strengths differ) | $1,587.82 per mL (Adalimumab-adaz(cf) pen 40 mg/0.4 mL) | $22,774.36 per mL (Skyrizi 150 mg/mL pen) |
| 12-month price change | -0.3% | +6% |
| Boxed warning | Yes | No |
| Shortage now | No current entry | No current entry |
| Recalls recorded | 1 | 0 |
| FAERS reports (a report is not proof of cause; counts follow how widely a medicine is used) | 712,308 | 81,290 |
| DEA schedule | none | none |
Source: Drugs@FDA, FDA NDC Directory, CMS NADAC of October 7, 2026, FDA shortages and recalls, FAERS via openFDA (FDA files October 8, 2026)
What next?
- Alternatives to adalimumab
- every medicine labeled for the same conditions